This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita (adalimumab-atto) was released in the
The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be ful
Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis' Lucentis (ranibizumab) for leading causes of blindness, raising the prospect o
Novartis and Roche's big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission approved Samsung Bioepis' copycat drug Byooviz.
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho